What happened\nAccording to data compiled by S&P Global Market Intelligence, genetics testing company Invitae's (NYSE: NVTA) stock was up 6% in price week to date as of Friday before market open. Investors reacted quite positively to news of a new company partnership with a heavy hitter in the pharmaceutical world.\nSo what\nThat partner is global pharmaceutical titan AstraZeneca (NASDAQ: AZN), which will utilize Invitae's Ciitizen natural history data in a clinical study of cholangiocarcinoma -- a rare form of bile duct cancer. Under the terms of the arrangement, Invitae and AstraZeneca will share this data, which derives from the community of advocacy group the Cholangiocarcinoma Foundation and has been provided by patient consent.\nInvitae did not divulge the financial terms of the data-sharing deal.\nIn the biotech company's press release heralding the arrangement, it quoted its general manager of patient network and data, Farid Vij, as saying that the deal "demonstrates that we can generate data at a level of quality that can inform key insights and decisions for both AstraZeneca and cholangiocarcinoma patients. We can't wait to see what important disease and treatment insights AstraZeneca learns from this meaningful cohort."\nNow what\nIt's hard to gauge the impact of any partnership deal on a company's finances and operations if little to no particulars are divulged.\nRegardless, AstraZeneca is a top name in the pharmaceutical world and this arrangement will almost certainly burnish Invitae's reputation, particularly in the segment of cutting-edge cancer diagnostics. Investors were well justified in trading the stock up on the news.\n10 stocks we like better than Invitae\nWhen our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\nThey just revealed what they believe are the ten best stocks for investors to buy right now... and Invitae wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n*Stock Advisor returns as of September 30, 2022\nEric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Invitae. The Motley Fool has a disclosure policy.\nThe views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.